Chapter 26
References
1. Beatty GL, Giantonio BJ. Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer. Expert Rev Anticancer Ther. 2008 May;8(5):683-8
2.
Rini BI,
Bukowski RM. Targeted therapy for metastatic renal cell carcinoma: a
home run or a work in progress? Oncology (Williston Park). 2008 Apr 15;22(4):388-96.
Weinstein IB, Joe A. Oncogene addiction. Cancer
Res. 2008 May 1;68(9):3077-80.
McCormack PL, Keam SJ. Bevacizumab: a review of its use in metastatic colorectal cancer. Drugs. 2008;68(4):487-506.
Bocchia M, Forconi F, Lauria F. Emerging drugs in chronic myelogenous leukaemia. Expert Opin Emerg Drugs. 2006 Nov;11(4):651-64.
Kunz M. Genomic signatures for individualized treatment of malignant tumors.
Curr Drug Discov Technol. 2008 Mar;5(1):9-14.
3. McCarty MF, Block KI. Toward a core nutraceutical program for cancer management. Integr Cancer Ther. 2006 Jun;5(2):150-71.
McCarty MF, Block KI. Multifocal angiostatic
therapy: an update. Integr Cancer Ther. 2005 Dec;4(4):301-14.
Yance DR Jr, Sagar SM. Targeting angiogenesis with integrative cancer therapies. Integr Cancer Ther. 2006 Mar;5(1):9-29.
4. Ornish D, Magbanua MJ, Weidner G, Weinberg V, Kemp C, Green C, Mattie MD, Marlin R, Simko J, Shinohara K, Haqq CM, Carroll PR. Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention. Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8369-74.
5. Roy S, Khanna S, Alessio HM, Vider J, Bagchi D, Bagchi M, Sen CK. Anti-angiogenic property of edible berries. Free Radic Res. 2002 Sep;36(9):1023-31.
Lee SJ, Lee HK. Sanguiin H-6 blocks endothelial cell growth through inhibition of VEGF binding to VEGF receptor. Arch Pharm Res. 2005 Nov;28(11):1270-4.
6. Banerjee S, Li Y, Wang Z, Sarkar FH. Multi-targeted therapy of cancer by genistein.
Cancer Lett. 2008 May 18. [Epub ahead of print]
7. Takei M, Tachikawa E, Hasegawa H, Lee JJ. Dendritic cells maturation promoted by M1 and M4, end products of steroidal ginseng saponins metabolized in digestive tracts, drive a potent Th1 polarization. Biochem Pharmacol. 2004 Aug 1;68(3):441-52.
Lee JK, Lee MK, Yun YP, Kim Y, Kim JS, Kim YS, Kim K, Han SS, Lee CK. Acemannan purified from Aloe vera induces phenotypic and functional maturation of immature dendritic cells. Int Immunopharmacol. 2001 Jul;1(7):1275-84.
Macatonia SE, Hosken NA, Litton M, Vieira P, Hsieh CS, Culpepper JA, Wysocka M, Trinchieri G, Murphy KM, O'Garra A. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol. 1995 May 15;154(10):5071-9.
8. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R. Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer. Clin Cancer Res. 2008 Jul 15;14(14):4491-4499.
Cruz-Correa M, Shoskes DA, Sanchez P, Zhao R, Hylind LM, Wexner SD, Giardiello
FM. Combination treatment with curcumin and
quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol
Hepatol. 2006 Aug;4(8):1035-8.
Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance.
Clin Cancer Res. 2004 Oct 15;10(20):6847-54.
Rafailov S, Cammack S, Stone BA, Katz AE. The role of Zyflamend, an herbal anti-inflammatory, as a potential chemopreventive agent against prostate cancer: a case report.
Integr Cancer Ther. 2007 Mar;6(1):74-6.
9. Morré DM, Morré DJ. Anticancer activity of grape and grape skin extracts alone and combined with green tea infusions. Cancer Lett. 2006 Jul 18;238(2):202-9.
10. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 2008 May 12. [Epub ahead of print]
Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol. 2006 Jan;69(1):195-206.
Choi BH, Kim CG, Lim Y, Shin SY, Lee YH. Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway. Cancer Lett. 2008 Jan 18;259(1):111-8.
Pal S, Bhattacharyya S, Choudhuri T, Datta GK, Das T, Sa G.
Amelioration of immune cell number depletion and potentiation of depressed
detoxification system of tumor-bearing mice by curcumin. Cancer Detect Prev.
2005;29(5):470-8
Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 2008 May 12. [Epub ahead of print]
Vanisree AJ, Ramanan R. In vitro assessment of curcumin against murine neuroblastoma cells. Neuro Endocrinol Lett. 2007 Apr;28(2):204-12.
Aggarwal B, Shishodia. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol. 2006; 71:1397-1421.
Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R. Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer. Clin Cancer Res. 2008 Jul 15;14(14):4491-4499.
Cruz-Correa M, Shoskes DA, Sanchez P, Zhao R, Hylind LM, Wexner SD, Giardiello
FM. Combination treatment with curcumin and
quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol
Hepatol. 2006 Aug;4(8):1035-8.
Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance.
Clin Cancer Res. 2004 Oct 15;10(20):6847-54.
11. Aggarwal B, Shishodia. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol. 2006; 71:1397-1421.
Morre DM, Morre DJ. Catechin-vanilloid synergies with potential clinical applications in cancer. Rejuvenation Res. 2006 Spring;9(1):45-55.
Takahashi H, Nomata K, Mori K, Matsuo M, Miyaguchi T, Noguchi M, Kanetake H.
The preventive effect of green tea on the gap junction intercellular communication in renal epithelial cells treated with a renal carcinogen. Anticancer Res. 2004 Nov-Dec;24(6):3757-62.
Yokoyama M, Noguchi M, Nakao Y, Pater A, Iwasaka
T. The tea polyphenol, (-)-epigallocatechin gallate effects on growth,
apoptosis, and telomerase activity in cervical cell lines. Gynecol Oncol. 2004
Jan;92(1):197-204.
Mittal A, Pate MS, Wylie RC, Tollefsbol TO,
Katiyar SK. EGCG down-regulates
telomerase in human breast carcinoma MCF-7 cells, leading to suppression of cell
viability and induction of apoptosis. Int J Oncol. 2004 Mar;24(3):703-10.
Stockfleth E, Beti H, Orasan R, Grigorian F, Mescheder A, Tawfik H, Thielert C.
Topical Polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial. Br J Dermatol. 2008 Jun;158(6):1329-38.
Henning SM, Aronson W, Niu Y, Conde F, Lee NH, Seeram NP, Lee RP, Lu J, Harris DM, Moro A, Hong J, Pak-Shan L, Barnard RJ, Ziaee HG, Csathy G, Go VL, Wang H, Heber D. Tea polyphenols and theaflavins are present in prostate tissue of humans and mice after green and black tea consumption. J Nutr. 2006 Jul;136(7):1839-43.
Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res. 2006 Jan 15;66(2):1234-40.
12. Ali MM, Vaidya V. Vitamin D and cancer. J Cancer Res Ther. 2007 Oct-Dec;3(4):225-30.
Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer. 2007 Sep;7(9):684-700.
Taghizadeh F, Tang MJ, Tai IT. Synergism between vitamin D and secreted protein acidic and rich in cysteine-induced apoptosis and growth inhibition results in increased susceptibility of therapy-resistant colorectal cancer cells to chemotherapy. Mol Cancer Ther. 2007 Jan;6(1):309-17.
Deeb KK, Trump DL, Johnson CS.Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer. 2007 Sep;7(9):684-700.
Jiang F, Bao J, Li P, Nicosia SV, Bai W. Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the down-regulation of telomerase. J Biol Chem. 2004 Dec 17;279(51):53213-21.
Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr. 2007 Jun;85(6):1586-91.
13. Raj MH, Abd Elmageed ZY, Zhou J, Gaur R, Nguyen L, Azam GA, Braley P, Rao PN, Fathi IM, Ouhtit A. Synergistic action of dietary phyto-antioxidants on survival and proliferation of ovarian cancer cells. Gynecol Oncol. 2008 Jul 4. [Epub ahead of print]
Alkhalaf M, El-Mowafy A, Renno W, Rachid O, Ali A, Al-Attyiah R. Resveratrol-induced apoptosis in human breast cancer cells is mediated primarily through the caspase-3-dependent pathway. Arch Med Res. 2008 Feb;39(2):162-8.
Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, Nair AS,
Shishodia S, Aggarwal BB. Resveratrol inhibits
proliferation, induces apoptosis, and overcomes chemoresistance through
down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and
cell survival gene products in human multiple myeloma cells.
Blood.
2007 Mar 15;109(6):2293-302.
Yang Y, Paik JH, Cho D, Cho JA, Kim CW. Resveratrol induces the suppression of tumor-derived CD4+CD25+ regulatory T cells. Int Immunopharmacol. 2008 Apr;8(4):542-7.
Sagar SM, Yance D, Wong RK. Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 2. Curr Oncol. 2006 Jun;13(3):99-107.
Tang FY, Su YC, Chen NC, Hsieh HS, Chen KS. Resveratrol inhibits migration and invasion of human breast-cancer cells. Mol Nutr Food Res. 2008 Jun;52(6):683-91.
Upham BL, Guzvić M, Scott J, Carbone JM, Blaha L, Coe C, Li LL, Rummel AM, Trosko JE. Inhibition of gap junctional intercellular communication and activation of mitogen-activated protein kinase by tumor-promoting organic peroxides and protection by resveratrol. Nutr Cancer. 2007;57(1):38-47.
Cao Y, Wang F, Liu HY, Fu ZD, Han R. Resveratrol induces apoptosis and differentiation in acute promyelocytic leukemia (NB4) cells. J Asian Nat Prod Res. 2005 Aug;7(4):633-41.
14. Kaur M, Singh RP, Gu M, Agarwal R, Agarwal C. Grape seed extract inhibits in vitro and in vivo growth of human colorectal carcinoma cells. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6194-202.
Engelbrecht AM, Mattheyse M, Ellis B, Loos B, Thomas M, Smith R, Peters S, Smith C, Myburgh K. Proanthocyanidin from grape seeds inactivates the PI3-kinase/PKB pathway and induces apoptosis in a colon cancer cell line. Cancer Lett. 2007 Dec 8;258(1):144-53
Yance DR Jr, Sagar SM. Targeting angiogenesis with integrative cancer therapies. Integr Cancer Ther. 2006 Mar;5(1):9-29.
Agarwal C, Singh RP, Dhanalakshmi S, Agarwal R.
Anti-angiogenic efficacy of grape seed extract in endothelial cells.
Oncol Rep. 2004 Mar;11(3):681-5.
Martínez Conesa C, Vicente Ortega V, Yáñez Gascón MJ, García Reverte JM, Canteras Jordana M, Alcaraz Baños M. [Experimental model for treating pulmonary metastatic melanoma using grape-seed extract, red wine and ethanol] Clin Transl Oncol. 2005 Apr;7(3):115-21.
15. Jiang J, Slivova V, Sliva D. Ganoderma lucidum inhibits proliferation of human breast cancer cells by down-regulation of estrogen receptor and NF-kappaB signaling. Int J Oncol. 2006 Sep;29(3):695-703.
Zaidman BZ, Wasser SP, Nevo E, Mahajna J. Androgen receptor-dependent and -independent mechanisms mediate Ganoderma lucidum activities in LNCaP prostate cancer cells. Int J Oncol. 2007 Oct;31(4):959-67.
Chen X, Hu ZP, Yang XX, Huang M, Gao Y, Tang W, Chan SY, Dai X, Ye J, Ho PC, Duan W, Yang HY, Zhu YZ, Zhou SF. Monitoring of immune responses to a herbal immuno-modulator in patients with advanced colorectal cancer.
Int Immunopharmacol. 2006 Mar;6(3):499-508.
Gao Y, Tang W, Dai X, Gao H, Chen G, Ye J, Chan E, Koh HL, Li X, Zhou S. Effects of water-soluble Ganoderma lucidum polysaccharides on the immune functions of patients with advanced lung cancer. J Med Food. 2005 Summer;8(2):159-68.
Gao Y, Zhou S, Jiang W, Huang M, Dai X. Effects of ganopoly (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients. Immunol Invest. 2003 Aug;32(3):201-15.
Thyagarajan A, Zhu J, Sliva D. Combined effect
of green tea and Ganoderma lucidum on invasive behavior of breast cancer cells.
Int J
Oncol. 2007 Apr;30(4):963-9.
Yuen JW, Gohel MD, Au DW.
Telomerase-associated apoptotic events by mushroom ganoderma lucidum on
premalignant human urothelial cells.
Nutr
Cancer. 2008 Jan-Feb;60(1):109-19.
16. Kodama N, Murata Y, Asakawa A, Inui A, Hayashi M, Sakai N, Nanba H. Maitake D-Fraction enhances antitumor effects and reduces immunosuppression by mitomycin-C in tumor-bearing mice. Nutrition. 2005 May;21(5):624-9.
Fullerton SA, Samadi AA, Tortorelis DG, Choudhury MS, Mallouh C, Tazaki H, Konno
S. Induction of apoptosis in human prostatic
cancer cells with beta-glucan (Maitake mushroom polysaccharide).
Mol Urol. 2000 Spring;4(1):7-13.
Kodama N, Asakawa A, Inui A, Masuda Y, Nanba H. Enhancement of cytotoxicity of NK cells by D-Fraction, a polysaccharide from Grifola frondosa. Oncol Rep. 2005 Mar;13(3):497-502.
Kodama N, Komuta K, Nanba H. Effect of Maitake
(Grifola frondosa) D-Fraction on the activation of NK cells in cancer patients.
J
Med Food. 2003 Winter;6(4):371-7.
Masuda Y, Murata Y, Hayashi M, Nanba H. Inhibitory effect of MD-Fraction on tumor metastasis: involvement of NK cell activation and suppression of intercellular adhesion molecule (ICAM)-1 expression in lung vascular endothelial cells. Biol Pharm Bull. 2008 Jun;31(6):1104-8.
17. Aggarwal B, Shishodia. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol. 2006; 71:1397-1421.
Seeram NP, Adams LS, Henning SM, Niu Y, Zhang Y, Nair MG, Heber D. In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem. 2005 Jun;16(6):360-7.
Edderkaoui M, Odinokova I, Ohno I, Gukovsky I, Go VL, Pandol SJ, Gukovskaya AS. Ellagic acid induces apoptosis through inhibition of nuclear factor kappa B in pancreatic cancer cells. World J Gastroenterol. 2008 Jun 21;14(23):3672-80.
Hayeshi R, Mutingwende I, Mavengere W, Masiyanise V, Mukanganyama S. The inhibition of human glutathione S-transferases activity by plant polyphenolic compounds ellagic acid and curcumin. Food Chem Toxicol. 2007 Feb;45(2):286-95.
Labrecque L, Lamy S, Chapus A, Mihoubi S, Durocher Y, Cass B, Bojanowski MW, Gingras D, Béliveau R. Combined inhibition of PDGF and VEGF receptors by ellagic acid, a dietary-derived phenolic compound. Carcinogenesis. 2005 Apr;26(4):821-6.
Losso JN, Bansode RR, Trappey A 2nd, Bawadi HA, Truax R.
In vitro anti-proliferative activities of ellagic acid.
J Nutr
Biochem. 2004 Nov;15(11):672-8.
Falsaperla M, Morgia G, Tartarone A, Ardito R, Romano
G. Support ellagic acid
therapy in patients with hormone refractory prostate cancer (HRPC) on standard
chemotherapy using vinorelbine and estramustine phosphate. Eur Urol. 2005 Apr;47(4):449-54.
Pantuck AJ, Leppert JT, Zomorodian N, Aronson W, Hong J, Barnard RJ, Seeram N,
Liker H, Wang H, Elashoff R, Heber D, Aviram M, Ignarro L, Belldegrun A.
Phase II study of pomegranate juice for men with rising prostate-specific
antigen following surgery or radiation for prostate cancer.
Clin Cancer
Res. 2006 Jul 1;12(13):4018-26.
18.
Boivin D, Blanchette M, Barrette S, Moghrabi A, Béliveau R.
Inhibition of cancer cell proliferation and suppression of TNF-induced
activation of NFkappaB by edible berry juice.
Anticancer Res. 2007 Mar-Apr;27(2):937-48.
Srivastava A, Akoh CC, Fischer J, Krewer G. Effect of anthocyanin fractions from selected cultivars of Georgia-grown blueberries on apoptosis and phase II enzymes. J Agric Food Chem. 2007 Apr 18;55(8):3180-5.
Karlsen A, Retterstøl L, Laake P, Paur I, Kjølsrud-Bøhn S, Sandvik L, Blomhoff R.
Anthocyanins inhibit nuclear factor-kappaB activation in monocytes and reduce plasma concentrations of pro-inflammatory mediators in healthy adults. J Nutr. 2007 Aug;137(8):1951-4. [chemotherapy resistance often mediated by NF-kappaB]
Bagchi D, Sen CK, Bagchi M, Atalay M.
Anti-angiogenic, antioxidant, and anti-carcinogenic properties of a novel
anthocyanin-rich berry extract formula. Biochemistry (Mosc). 2004 Jan;69(1):75-80.
Duthie SJ. Berry phytochemicals, genomic
stability and cancer: evidence for
chemoprotection at several stages in the carcinogenic process. Mol Nutr Food
Res. 2007 Jun;51(6):665-74.
Serafino A, Sinibaldi-Vallebona P, Lazzarino G, Tavazzi B, Rasi G, Pierimarchi P, Andreola F, Moroni G, Galvano G, Galvano F, Garaci E. Differentiation of human melanoma cells induced by cyanidin-3-O-beta-glucopyranoside. FASEB J. 2004 Dec;18(15):1940-2.
19. Bagli E, Stefaniotou M, Morbidelli L, Ziche M, Psillas K, Murphy C, Fotsis T. Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3'-kinase activity. Cancer Res. 2004 Nov 1;64(21):7936-46.
Kim JH, Lee EO, Lee HJ, Ku JS, Lee MH, Yang DC, Kim SH. Caspase activation and extracellular signal-regulated kinase/Akt inhibition were involved in luteolin-induced apoptosis in Lewis lung carcinoma cells. Ann N Y Acad Sci. 2007 Jan;1095:598-611.
Lee WJ, Wu LF, Chen WK, Wang CJ, Tseng TH. Inhibitory effect of luteolin on hepatocyte growth factor/scatter factor-induced HepG2 cell invasion involving both MAPK/ERKs and PI3K-Akt pathways. Chem Biol Interact. 2006 Mar 25;160(2):123-33.
Takahashi T, Kobori M, Shinmoto H, Tsushida T. Structure-activity relationships of flavonoids and the induction of granulocytic- or monocytic-differentiation in HL60 human myeloid leukemia cells. Biosci Biotechnol Biochem. 1998 Nov;62(11):2199-204.